These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18508151)

  • 1. Drug formulary decision-making in two regional health authorities in British Columbia, Canada.
    Armstrong K; Mitton C; Carleton B; Shoveller J
    Health Policy; 2008 Dec; 88(2-3):308-16. PubMed ID: 18508151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
    Summers KH; Szeinbach SL
    Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective decision-making in a changing healthcare environment: a P & T Committee interview.
    Zoloth A; Yon JL; Woolf R
    Hosp Formul; 1989 Feb; 24(2):85-7, 90, 93 passim. PubMed ID: 10291815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
    Adams J; Richardson J
    Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities.
    Mittmann N; Knowles S
    Can J Clin Pharmacol; 2009; 16(1):e171-7. PubMed ID: 19242000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulary evaluation of third-generation cephalosporins using decision analysis.
    Cano SB; Fujita NK
    Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion of innovation I: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals--a hospital pharmacy perspective.
    D'Sa MM; Hill DS; Stratton TP
    Can J Hosp Pharm; 1994 Dec; 47(6):254-60. PubMed ID: 10139270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing the P & T committee agenda for new drug requests.
    Standish RC; Evans PJ; Bell JE
    Hosp Formul; 1984 Sep; 19(9):792, 795-800. PubMed ID: 10267929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the British Columbia reference drug program on hospital formularies: a survey of hospital pharmacy managers.
    Gill NJ; Frighetto L; Marra C; Jewesson P
    Can J Clin Pharmacol; 2000; 7(2):109-14. PubMed ID: 10958707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to use structured decision making in developing therapeutic, cost-effective formulary systems.
    Crane VS
    Hosp Formul; 1993 Oct; 28(10):859-62, 865-7. PubMed ID: 10129135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P & T Committee formulary requests: criteria for admission.
    Weintraub M; Guttmacher L
    Hosp Formul; 1984 Oct; 19(10):975-7, 980. PubMed ID: 10268315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion of innovation II: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals--a drug development perspective.
    D'Sa MM; Hill DS; Stratton TP
    Can J Hosp Pharm; 1995 Feb; 48(1):7-15. PubMed ID: 10141063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing nature of nursing work in rural and small community hospitals.
    Montour A; Baumann A; Blythe J; Hunsberger M
    Rural Remote Health; 2009; 9(1):1089. PubMed ID: 19199373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-tier drugs assessment in a decentralised health care system. The Italian case-study.
    Jommi C; Costa E; Michelon A; Pisacane M; Scroccaro G
    Health Policy; 2013 Oct; 112(3):241-7. PubMed ID: 23850166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.